Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eyeing Solo U.S. Debut, EU Biotech ThromboGenics Preps Ocriplasmin For Launch

Executive Summary

Small European biotechs usually build their business in their home region first, and later look to the US for growth. Belgium's ThromboGenics is doing the opposite; it aims to launch its lead product initially in the US, and will tackle Europe after partner and market leader Alcon paves the way.


Related Content

ThromboGenics’ Jetrea Clears Advisory Panel, But Questions On Population Size Remain
ThromboGenics Ocriplasmin’s Advisory Panel Likely To Focus On Safety
Alcon Grabs Ex-U.S. Rights To ThromboGenics' Retina Adhesion Therapy Ocriplasmin In $500 Mil. Deal
Retinal Disease: Much Progress, Some Pain
ThromboGenics Delays Diabetic Retinopathy Study; On Track To File Ocriplasmin For Retinal Adhesions
European Specialty Pharma In Transition: Is A U.S. Presence Necessary?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts